OptimizeRx Corp. (NASDAQ:OPRX) Sees Significant Decline in Short Interest

OptimizeRx Corp. (NASDAQ:OPRX) was the target of a large decline in short interest during the month of June. As of June 30th, there was short interest totaling 1,129,328 shares, a decline of 39.0% from the June 15th total of 1,851,668 shares. Based on an average daily volume of 624,522 shares, the short-interest ratio is presently 1.8 days. Approximately 6.5% of the company’s stock are short sold.

Analyst Ratings Changes

OPRX has been the topic of a number of analyst reports. B. Riley Financial lowered their price objective on OptimizeRx from $11.00 to $10.00 and set a “buy” rating on the stock in a report on Wednesday, May 13th. Zacks Research lowered OptimizeRx from a “strong-buy” rating to a “hold” rating in a report on Monday, May 4th. Stephens decreased their target price on OptimizeRx from $10.00 to $7.00 and set an “equal weight” rating for the company in a research report on Wednesday, May 13th. UBS Group set a $10.00 price target on OptimizeRx in a report on Wednesday, May 13th. Finally, Weiss Ratings downgraded OptimizeRx from a “sell (d+)” rating to a “sell (d)” rating in a report on Thursday, May 14th. Six research analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $13.43.

OptimizeRx Stock Performance

Shares of OptimizeRx stock traded up $0.13 during trading on Thursday, reaching $6.78. The company’s stock had a trading volume of 68,436 shares, compared to its average volume of 451,646. OptimizeRx has a one year low of $4.54 and a one year high of $22.25. The company has a debt-to-equity ratio of 0.16, a quick ratio of 5.37 and a current ratio of 5.37. The firm has a market cap of $127.27 million, a price-to-earnings ratio of 19.39 and a beta of 1.08. The business’s fifty day moving average price is $5.46 and its 200-day moving average price is $7.59.

OptimizeRx (NASDAQ:OPRX) last announced its earnings results on Tuesday, May 12th. The company reported $0.14 earnings per share for the quarter, beating the consensus estimate of $0.01 by $0.13. The firm had revenue of $19.84 million during the quarter, compared to the consensus estimate of $18.74 million. OptimizeRx had a return on equity of 10.86% and a net margin of 6.37%. As a group, equities research analysts predict that OptimizeRx will post 0.51 earnings per share for the current year.

Institutional Investors Weigh In On OptimizeRx

Several hedge funds have recently modified their holdings of the business. Vanguard Group Inc. increased its position in OptimizeRx by 15.0% during the third quarter. Vanguard Group Inc. now owns 1,059,109 shares of the company’s stock worth $21,712,000 after acquiring an additional 138,224 shares during the period. Royce & Associates LP boosted its holdings in OptimizeRx by 0.7% in the 4th quarter. Royce & Associates LP now owns 682,030 shares of the company’s stock valued at $8,362,000 after purchasing an additional 4,700 shares during the period. Kennedy Capital Management LLC grew its position in OptimizeRx by 42.8% in the 3rd quarter. Kennedy Capital Management LLC now owns 674,918 shares of the company’s stock worth $13,836,000 after purchasing an additional 202,446 shares during the last quarter. Rice Hall James & Associates LLC grew its position in OptimizeRx by 1.9% in the 1st quarter. Rice Hall James & Associates LLC now owns 601,921 shares of the company’s stock worth $3,780,000 after purchasing an additional 11,247 shares during the last quarter. Finally, Dimensional Fund Advisors LP grew its position in OptimizeRx by 22.3% in the 1st quarter. Dimensional Fund Advisors LP now owns 563,570 shares of the company’s stock worth $3,540,000 after purchasing an additional 102,661 shares during the last quarter. 76.47% of the stock is owned by institutional investors.

About OptimizeRx

OptimizeRx, Inc is a healthcare technology company that operates a digital health network designed to facilitate communication between pharmaceutical manufacturers, payers and healthcare providers. Through its cloud-based platform, OptimizeRx delivers targeted digital interventions—such as patient savings messages, clinical content and product information—directly into electronic health record (EHR) workflows at the point of care. By integrating with leading EHR systems, the company helps life sciences organizations optimize brand engagement, improve patient adherence and support informed prescribing decisions.

The company’s core offerings include digital prescription benefit notifications, co-pay assistance alerts and real-time clinical messaging tailored to specific patient populations.